Obalon (NASDAQ:OBLN) & Caladrius (CLBS): 2 Soaring Life Science Stocks


  • Obalon’s stock boomed over 414 per cent over its merger announcement with ReShape, its 446 million shares traded on NASDAQ.
  • Stocks of Caladrius Bioscience skyrocketed by 77 per cent on the back of its Phase-2 trial initiation for CLBS16, a respiratory therapy.
  • In the last one month, Obalon has returned 441 per cent. Meanwhile, Caladrius’ shares have swelled by nearly 94 per cent. 

Obalon Therapeutics Inc. (US:OBLN or NASDAQ: OBLN) rose as much as 414 per cent on Wednesday, January 20, after its merger announcement with ReShape Lifesciences Inc. (OTCQB:RSLS), an obesity therapeutics firm. Both the companies have agreed to combine their weight-loss technologies.

Caladrius Biosciences, Inc. (CLBS:US or NASDAQ: CLBS), a biopharmaceutical company, has started its clinical Phase-2 trial of CLBS16 – the treatment for coronary microvascular problems. The biopharma stock surged by over 77 per cent on Wednesday.

Life science companies continue to trend in North American markets. These growth stocks have advanced on the basis of their research and development (R&D). Let us analyze market fundamentals of these two bioscience stocks:


Obalon Therapeutics Inc. (US:OBLN or NASDAQ: OBLN) 

Current Stock Price: US$ 8.28


Stocks of the biotech firm has popped up 441 per cent in the last one month, with an average trading volume of 23 million on the NASDAQ.

The trading volume of the stock skyrocketed to approximately 446 million on Wednesday – nearly 20 times rise compared to its last 30-day average volume. Obalon has total listed shares outstanding of 7.77 million.

The biopharma shares have a debt-to-equity ratio of 0.26 and a price-to-debt ratio of 10.895, as per data on the TMX portal.

The weight loss solution provider registered R&D expenses of US$ 0.3 million for the third quarter of 2020, a 300 per cent decrease year-over-year.

Caladrius Biosciences Inc. (CLBS:US or NASDAQ: CLBS)

Current Stock Price: US$ 2.89


The bioscience company is developing a therapy for coronary microvascular dysfunction found in COVID-19 positive patients.

The CLBS stock has gained nearly 94 per cent, with an average volume of almost 13 million in the last one month. Nearly 127.8 million scrips traded in the markets on Wednesday, after the company announced the Phase-2 clinical trial of CLBS16.

The healthcare stock has over 39 million listed outstanding shares, with a price-to-book ratio of 1.482 and a debt-to-equity ratio of 0.02.

In its third quarter ended on September 30, 2020, R&D expenses were roughly US$3.0 million, which coincided with the third quarter of 2019.


The website https://kalkinemedia.com/ca is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001. The principal purpose of the content on the website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK